Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | LTB4R | Q15722 | 6/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 6/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902570 | 0.92 | LTB4R (0.52) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6806830 | 0.87 | SLC6A9 (0.41) | NR1H4LTB4RLTB4R2PTGER1PTGER4 | |
| SCHEMBL8581492 | 0.84 | HTR1A (0.51) | NR1H4HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6807773 | 0.83 | NR1H4 (0.47) | NR1H4HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL8585279 | 0.83 | NR1H4 (0.47) | NR1H4LTB4RHTR1AADRA1DADRA1A | |
| SCHEMBL8582404 | 0.82 | NR1H4 (0.46) | NR1H4HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL6756237 | 0.82 | NR1H4 (0.52) | NR1H4LTB4RLTB4R2C5AR1 | |
| SCHEMBL8561280 | 0.81 | LTB4R (0.51) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6757622 | 0.81 | NR1H4 (0.51) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL6757535 | 0.80 | LTB4R (0.50) | NR1H4LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673813-B2 | INHIBITING MEMBRANE TRANSPORT MEDIATED BY THE MULTIDRUG RESISTANCE ASSOCIATED PROTEIN MRP IN A PATIENT BY ADMINISTERING A COMPOUND HAVING AN AMPHIPHILIC ANION AND A MOLECULAR WEIGHT OF FROM 300 TO 950 DALTONS. | JEDLITSCHKY GABRIELE (DE) | 2004-01-06 | — | — | US | disclosed |
| EP-0964683-A4 | LEUKOTRIENE ANTAGONISTS FOR ORAL SQUAMOUS CELL CARCINOMA | LILLY CO ELI (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-0961617-A4 | LEUKOTRIENE ANTAGONISTS FOR CEREBRAL FOCAL STROKE | LILLY CO ELI (US) | 2002-08-07 | — | — | EP | disclosed |
| US-20020013370-A1 | Methods for identifying and treating resistant tumors | SAWYER JASON SCOTT (US) | 2002-01-31 | — | — | US | disclosed |
| US-20020010213-A1 | Methods for identifying and treating resistant tumors | SAWYER JASON SCOTT (US) | 2002-01-24 | — | — | US | disclosed |
| EP-1129707-A2 | Methods for identifying and treating resistant tumors | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2001-09-05 | — | — | EP | disclosed |
| US-6235785-B1 | DRUG RESISTANCE | ELI LILLY AND COMPANY | 2001-05-22 | — | — | US | disclosed |
| EP-0964683-A1 | LEUKOTRIENE ANTAGONISTS FOR ORAL SQUAMOUS CELL CARCINOMA | ELI LILLY AND COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0961617-A1 | LEUKOTRIENE ANTAGONISTS FOR CEREBRAL FOCAL STROKE | ELI LILLY AND COMPANY (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5998454-A | ANTIINFLAMMATORY AGENT; EYES | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0743064-A1 | Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease | ELI LILLY AND COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| EP-0735870-A1 | USE OF PLA 2? INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5563164-A | TREATING ARTHRITIS, PSORIASIS, ASTHMA, INFLAMMATORY BOWEL DISEASE, OR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| US-5543428-A | ADMINISTERING SUBSTITUTED PHENOXYALKYL COMPOUNDS TO REVERSE DRUG RESISTANCE | ELI LILLY AND COMPANY (US) | 1996-08-06 | — | — | US | disclosed |
| WO-1996006604-A2 | METHODS FOR IDENTIFYING AND TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-03-07 | — | — | WO | disclosed |
| US-5478857-A | Administering inhibitor of phospholipase A2 | ELI LILLY AND COMPANY (US) | 1995-12-26 | — | — | US | disclosed |
| US-5462954-A | Antiinflammatory, antiallergens; treating asthma | ELI LILLY AND COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995017183-A1 | USE OF PLA2 INHIBITORS AS TREATMENT FOR ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| CN-1088906-A | The phenyl phenol leukotriene antagonists that replaces | LILLY CO ELI (US) | 1994-07-06 | — | — | CN | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013370-A1 | Methods for identifying and treating resistant tumors | ABCC1, SLC11A2, VHL | NR1H4 222/4885LTB4R 1827/4885LTB4R2 2396/4885 |
| US-20020010213-A1 | Methods for identifying and treating resistant tumors | ABCC1, SLC11A2, VHL | NR1H4 222/4885LTB4R 1827/4885LTB4R2 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.